Regulation of the signal transduction program by drugs

Weber, 1983, Biochemical strategy of cancer cells and the design of chemotherapy: G.H.A. Clowes Memorial Lecture, Cancer Res., 43, 3466 Rizzo, 1994, 1-Phosphatidylinositol 4-kinase (EC 2.7.1.67): an enzyme linked with proliferation and malignancy, Cancer Res., 54, 2611 Singhal, 1994, 1-Phosphatidylinositol 4-phosphate 5-kinase (EC 2.7.1.68): a proliferation-and malignancy-linked signal transduction enzyme, Cancer Res., 54, 5574 Yang, 1997 Singhal, 1994, Coordinated increase in activities of the signal transduction enzymes PI kinase and PIP kinase in human cancer cells, Life Sci., 55, 1487, 10.1016/0024-3205(94)00690-3 Singhal, 1995, Quercetin down-regulates signal transduction in human breast carcinoma cells, Biochem. Biophys. Res. Commun., 208, 425, 10.1006/bbrc.1995.1355 Prajda, 1995, Linkage of reduction in 1-phosphatidylinositol 4-kinase activity and inositol 1,4,5-trisphosphate concentration in human ovarian carcinoma cells treated with quercetin, Life Sci., 56, 1587, 10.1016/0024-3205(95)00125-P Weber, 1995, Regulation of signal transduction, Advan. Enzyme Regul., 35, 1, 10.1016/0065-2571(94)00007-P Look, 1992, Inhibition by tiazofurin of inosine 5′-phosphate dehydrogenase (IMP DH) activity in extracts of ovarian carcinomas, Gyn. Oncol., 47, 66, 10.1016/0090-8258(92)90078-W Prajda, 1988, Enzymic programs of rat bone marrow and the impact of acivicin and tiazofurin, Biochem. Pharmacol., 37, 875, 10.1016/0006-2952(88)90175-X Weber, 1996, Current issues in regulation of signal transduction, Advan. Enzyme Regul., 36, 33, 10.1016/0065-2571(96)00003-9 Weber, 1971, Metabolism of hepatomas of different growth rates in situ and during ischemia, Cancer Res., 31, 2177 Lowry, 1951, Protein measurement with the Folin phenol reagent, J. Biol. Chem., 193, 265, 10.1016/S0021-9258(19)52451-6 Weber, 1996, Increased signal transduction activity and down-regulation in human cancer cells, Anticancer Res., 16, 3271 Jackson, 1975, IMP dehydrogenase, an enzyme linked with proliferation and malignancy, Nature, 256, 331, 10.1038/256331a0 Weber, 1996, Tiazofurin: molecular and clinical action, Anticancer Res., 16, 3313 Natsumeda, 1990, Two distinct cDNAs for human IMP dehydrogenase, J. Biol. Chem., 265, 5292, 10.1016/S0021-9258(19)34120-1 Konno, 1991, Expression of human IMP dehydrogenase types I and II in Escherichia coli and distribution in human normal and leukemic cell lines, J. Biol. Chem., 266, 508, 10.1016/S0021-9258(18)52465-0 Nagai, 1991, Selective up-regulation of type II inosine 5′-monophosphate dehydrogenase messenger RNA expression in human leukemias, Cancer Res., 51, 3886 Weber, 1976, Key enzymes of IMP metabolism: transformation-and progression-linked alterations in gene expression, Advan. Enzyme Regul., 14, 3, 10.1016/0065-2571(76)90005-4 Weber, 1977, Enzymology of cancer cells, part 1, New Engl. J. Med., 296, 486, 10.1056/NEJM197703032960905 Weber, 1977, Enzymology of cancer cells, part 2, New Engl. J. Med., 296, 541, 10.1056/NEJM197703102961005 Robins, 1982, Nucleoside and nucleotide inhibitors of inosine monophosphate (IMP) dehydrogenase as potential antitumor inhibitors, Nucleosides & Nucleotides, 1, 35, 10.1080/07328318208079400 Tricot, 1989, Biochemically directed therapy of leukemia with tiazofurin, a selective blocker of inosine 5′-phosphate dehydrogenase activity, Cancer Res., 49, 3696 Tricot, 1996, Biochemically targeted therapy of refractory leukemia and myeloid blast crisis of chronic granulocytic leukemia with tiazofurin, a selective blocker of inosine 5′-monophosphate dehydrogenase (IMPDH) activity, Anticancer Res., 16, 3341 Tricot, 1990, Tiazofurin: biological effects and clinical uses, Intl. J. Cell Cloning, 8, 161, 10.1002/stem.5530080303 Prajda, 1993, Sequential impact of tiazofurin and ribavirin on enzymic program of rat bone marrow, Cancer Res., 53, 5982 Wright, 1996, Tiazofurin effects on IMP dehydrogenase activity and expression in the leukemic cells of patients with CML in blast crisis, Anticancer Res., 16, 3349 Olah, 1988, Induction of erythroid differentiation and modulation of gene expression by tiazofurin in K562 leukemia cells, 85, 6533 Olah, 1990, Down-regulation of c-myc and c-Ha-ras gene expression by tiazofurin in rat hepatoma cells, Cancer Biochem. Biophys., 11, 107 Weber, 1991, Tiazofurin down-regulates expression of c-Ki-ras oncogene in a leukemic patient, Cancer Commun., 3, 61, 10.3727/095535491820873579 Olah, 1996, Molecular mechanisms in the antiproliferative action of taxol and tiazofurin, Anticancer Res., 16, 1 Csokay, 1997, Molecular mechanisms in the antiproliferative action of quercetin, Life Sci., 10.1016/S0024-3205(97)00230-0 Lui, 1984, Modulation of IMP dehydrogenase activity and guanylate metabolism by tiazofurin (2-β-d-ribofuranosylthiazole-4-carboxamide), J. Biol. Chem., 259, 5078, 10.1016/S0021-9258(17)42958-9 Hata, 1993, Tiazofurin decreases Ras-GTP complex in K562 cells, Oncol. Res., 5, 161 Nishioka, 1989, Screening of phosphatidylinositol kinase inhibitors from streptomyces, J. Antibiotics, 42, 823, 10.7164/antibiotics.42.823 Peterson, 1995, Evaluation of the biochemical targets of genistein in tumor cells, J. Nutr., 125, 784S Barnes, 1995, Biochemical targets of the isoflavone genistein in tumor cell lines (43840), 208, 103 Constantinou, 1995, Genistein as an inducer of tumor cell differentiation: possible mechanisms of action (43841), 208, 109 Makishima, 1991, Effects of inhibitors of protein tyrosine kinase activity and/or phosphatidylinositol turnover on differentiation of some human myelomonocytic leukemia cells, Leuk. Res., 15, 701, 10.1016/0145-2126(91)90072-2 Ozaki, 1993, Effects of genistein, a tyrosine kinase inhibitor, on platelet functions, Biochem. Pharmacol., 46, 395, 10.1016/0006-2952(93)90515-X Matsukawa, 1993, Genistein arrests cell cycle progression at G2-M, Cancer Res., 53, 1328 Yanagihara, 1993, Antiproliferative effects of isoflavones on human cancer cell lines established from the gastrointestinal tract, Cancer Res., 53, 5815